Linaclotide to Lead the Global Chronic Idiopathic
Constipation Drugs Market at a CAGR over 7% during 2016 - 2022
The latest
market report published by Credence Research, Inc. “Global Chronic Idiopathic
Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive
Analysis, and Forecast, 2016-2022,”
The chronic
idiopathic constipation (CIC) drugs market was valued at USD 1675.4 Mn in 2015,
and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4%
from 2016 to 2022; where Europe has the largest market share.
Browse the full report Chronic Idiopathic Constipation
(CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and
Forecast, 2016–2022 report at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Market Insights
Chronic
idiopathic constipation (CIC) is a common gastrointestinal disorder. The
currently available treatment options, both prescription based and OTC have
demonstrated limited efficacy in a considerable set of patients. Thus there is
a major demand for more effective medications for the treatment of CIC.
Linaclotide is a secretagogue and has novel action mechanism; it has low oral
bioavailability and has demonstrated the least systemic side effects. Through
several clinical trials, Linaclotide has demonstrated greater efficacy in
treating both CIC and irritable bowel syndrome induced constipation.
Currently
North America is the largest regional market for CIC drugs at a market share of
approximately 50%. It is also expected that the region will progress at the
fastest CAGR of above 8% during the forecast period. Higher awareness among
physicians and patient population significantly contribute the market growth in
the region. Earliest commercialization of the drug in the US also adds up to
the high demand of the drug in North America market.
On the other
hand, gradual introduction of Linaclotide in other developing markets will
facilitate market growth in Asia Pacific market. China, Japan, Australia and
India are the major national markets that are expected to give highest revenue
contributions to the Asia Pacific CIC drugs market. Also, supporting the
established fact of correlation between age and risk of CIC, it is reported
that China and Japan will be the largest national markets for CIC drugs in Asia
Pacific.
For More
Reports Related to This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market
Overall, the
CIC drugs market is open for further innovations, anticipating introduction of
novel therapeutic options in the global market. Intensive research and
development activities undertaken by the major market players indicate further
competition in the market in the next ten years.
About Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales
Manager)
Address:
105 N 1st ST #429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
No comments:
Post a Comment